James Patrick Ryan Sells 180 Shares of Analogic Co. (ALOG) Stock
Analogic Co. (NASDAQ:ALOG) insider James Patrick Ryan sold 180 shares of the firm’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $73.60, for a total transaction of $13,248.00. Following the completion of the sale, the insider now directly owns 1,310 shares in the company, valued at approximately $96,416. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
James Patrick Ryan also recently made the following trade(s):
- On Monday, April 17th, James Patrick Ryan sold 180 shares of Analogic stock. The stock was sold at an average price of $71.25, for a total transaction of $12,825.00.
- On Wednesday, March 15th, James Patrick Ryan sold 180 shares of Analogic stock. The stock was sold at an average price of $74.65, for a total transaction of $13,437.00.
- On Wednesday, February 15th, James Patrick Ryan sold 180 shares of Analogic stock. The stock was sold at an average price of $81.10, for a total transaction of $14,598.00.
Shares of Analogic Co. (NASDAQ:ALOG) traded down 2.07% during midday trading on Tuesday, reaching $73.35. 143,717 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $73.02 and its 200-day moving average is $79.90. Analogic Co. has a 12-month low of $69.65 and a 12-month high of $95.85. The stock has a market cap of $916.07 million, a PE ratio of 39.37 and a beta of 0.85.
Analogic (NASDAQ:ALOG) last posted its quarterly earnings results on Monday, March 6th. The medical research company reported $0.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.21. The company had revenue of $131.50 million for the quarter, compared to the consensus estimate of $130.45 million. Analogic had a net margin of 2.58% and a return on equity of 7.14%. The firm’s revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 EPS. On average, equities analysts expect that Analogic Co. will post $3.18 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/05/16/james-patrick-ryan-sells-180-shares-of-analogic-co-alog-stock.html.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Analogic by 54,561.6% in the first quarter. BlackRock Inc. now owns 1,601,037 shares of the medical research company’s stock valued at $121,518,000 after buying an additional 1,598,108 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Analogic by 104.9% in the first quarter. Bank of New York Mellon Corp now owns 368,958 shares of the medical research company’s stock valued at $28,004,000 after buying an additional 188,891 shares during the last quarter. William Blair Investment Management LLC acquired a new position in shares of Analogic during the fourth quarter valued at about $13,488,000. Norges Bank acquired a new position in shares of Analogic during the fourth quarter valued at about $8,170,000. Finally, Wells Fargo & Company MN boosted its position in shares of Analogic by 14.5% in the first quarter. Wells Fargo & Company MN now owns 771,025 shares of the medical research company’s stock valued at $58,521,000 after buying an additional 97,657 shares during the last quarter.
Separately, Sidoti initiated coverage on shares of Analogic in a report on Monday, January 23rd. They issued a “neutral” rating and a $88.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $91.00.
Analogic Corporation designs, manufactures and commercializes guidance, diagnostic imaging and threat detection technologies. The Company operates through three segments: Medical Imaging, Ultrasound, and Security and Detection. The Company’s Medical Imaging segment provides medical imaging systems and subsystems for computed tomography (CT), magnetic resonance imaging (MRI) and high-resolution digital mammography.
Receive News & Ratings for Analogic Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Analogic Co. and related companies with MarketBeat.com's FREE daily email newsletter.